Close Menu
    What's Hot

    Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

    November 11, 2026

    Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

    November 11, 2026

    Editor’s Letter – Volume 2, Issue 11, November 2026

    November 11, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Symetra and TIAA Partner To Launch Mariner Re

      October 27, 2026

      Chariot Re Announces Fourth Reinsurance Transaction, First Covering Japanese Liabilities

      October 15, 2026

      Pacific Life Re Executes First Asset-Intensive Reinsurance Transaction in Hong Kong

      September 9, 2026

      Bermuda Life & Annuity Sidecar Market Quadruples as Alternative Asset Manager/Life Insurance Convergence Continues

      September 9, 2026

      Q&A: Alexandr Dudarev, CEO, Inshurik

      October 28, 2026

      Is Dementia the Next Big Longevity Event?

      October 15, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 11, 2026

      Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

      November 11, 2026

      Sponsor Demand Intact as US Pension Risk Transfer Market Prepares for Busy Year-End

      November 11, 2026

      Delcam Retirement Benefits Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 5, 2026

      Record Low Mortality Rates So Far in 2026 in England and Wales, Says CMI

      October 12, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

      November 11, 2026
      Litigation

      Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

      November 11, 2026

      Life Insurance Settlement Association Announces New Chair, Composition of Board for 2027

      November 11, 2026

      UK Equity Release Activity Nudges Higher in Third Quarter

      October 28, 2026

      Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 11, 2026

      Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

      November 11, 2026

      Editor’s Letter – Volume 2, Issue 11, November 2026

      November 11, 2026

      Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

      November 11, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 11, November 2026

      November 11, 2026
      Life Risk News Editors Letter

      Editor’s Letter – Volume 2, Issue 10, October 2026

      October 15, 2026

      Editor’s Letter – Volume 2, Issue 9, September 2026

      September 9, 2026

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    New Research Set to Have Significant Impact on Longevity and Mortality Markets

    Mortality November 13, 2024By Greg Winterton
    Share
    Twitter LinkedIn Email

    The average life expectancy of a newborn human in 1900 was 32 years, and according to Our World in Data, by 2021, that more than doubled, to 71 years.

    So, what are the chances then that the next 100 years or so brings about a similar jump?

    Pretty much zero, according to Implausibility Of Radical Life Extension In Humans In The Twenty-First Century, a new article published in Nature Aging from longevity experts S. Jay Olshansky, Bradley J. Wilcox, Lloyd Demetrius and Hiram Beltran-Sanchez.

    The quartet’s research used demographic survivorship metrics from national vital statistics in Australia, France, Hong Kong, Italy, Japan, South Korea, Spain, Sweden, Switzerland and the US from 1990 to 2019 and found that improvements in life expectancy had slowed down since 1990, ultimately concluding that under the best of conditions, only about 15% of females and 5% of males could survive to 100 years of age in the 21st century.

    The impact of the findings will be felt across health systems, urban planning and retirement planning the world over, and certainly, for companies in the longevity and morality markets, as well; but for Olshansky, the cat has been out of the bag for a long time.

    “We made this prediction – that life expectancy had to slow down – in 1990. It’s not about curing this and that and AI – unless it influences aging, it’s not going to work. Aging is currently immutable.”

    Longevity risk is prevalent in many industries, ranging from the niche, such as life ILS and life settlements, to the broader, such as reverse mortgages and defined benefit pensions.

    In life settlements and reverse mortgages in particular, the findings of the research may be felt less keenly.

    “Life settlement fund managers are obviously concerned about right tail risk, and rightly so. That still exists at the individual level – after all, those who are most likely to make it to 100 are those in their late 90s, so a life settlement fund with these policies still has this risk,” said Olshansky.

    “And there’s also a legitimate concern about right tail risk in the Hong Kong reverse mortgage market. 12-13% of Hong Kong females already live to 100 – that’s way higher than anywhere else in the world. Reverse mortgage providers can be exposed here,” he added.

    But at the life insurance and population levels, the impact could be profound.

    It is generally accepted that life insurers do account for potential improvements in mortality in their actuarial models, but if they have been taking too conservative an approach, then making adjustments could mean that life insurance becomes more accessible to the broader population.

    In the US, for example, industry group Life Insurance Marketing and Research Association (LIMRA) and Life Happens publish The Insurance Barometer, an annual study that tracks the perceptions, attitudes, and behaviours of adult consumers in the United States, with a particular focus on life insurance. This year’s edition reports that while around half of Americans have life insurance, 42% say they need more and the main reason given for not purchasing life insurance is that it’s too expensive.

    Will this new research mean that life insurers can revisit their mortality modelling effort to identify where they might have been too conservative on risk – and perhaps, bring down pricing?

    “I’m guessing that’s exactly what’s going to happen. It’s obviously more nuanced than that – they will need to do a little more homework to make sure the dynamics apply directly to the populations they are underwriting, as there will be variations. But I do think that many of them will look at their existing pricing and modelling assumptions because they are probably going to be wrong, and the longer the forecasts go to the future, the more wrong they will be,” said Olshansky.

    It’s a similar situation in the pension risk transfer (PRT) market. These deals can involve thousands of retirees: Just recently, RAC secured a deal with Aviva to insure the pension liabilities of approximately 19,000 people. General population mortality data is also applicable to this industry, and according to David Blake, Professor of Finance & Director of Pensions Institute at Bayes Business School, getting this right is no easy task.

    “Getting the trend increase in life expectancy right is the key job of the pricing actuaries appointed by life insurers. If they underestimate the trend, then their pricing will be too low, and this will eventually eat into reserves. If they do the opposite, they will be overpricing. It is a fine line,” he said.

    If the models are indeed overcompensating for increasing life expectancy, however, the likelihood that there would be any kind of pause in bulk purchase annuity transaction activity whilst insurers review and tweak their pricing is low.

    “Pricing changes every day in the light of new information. If the new information points to a significant slowdown or even a flattening of the trend, then prices will respond immediately. Each insurer will look at what its competitors are doing to confirm that it has made the right decision – the prices won’t jump, they will change slowly. But there will be no pause in PRT activity,” said Blake.

    Only time will tell in terms of whether life insurers around the world adjust their pricing, whether that be for life insurance policies, pension risk transfer deals or annuities. After all, life expectancy is not the only determinant of price. But according to Olshansky, they have begun to take action.

    “We’re already seeing actuaries at insurers scrambling in terms of how to adjust their approach to future mortality,” he said.

    “Because if insurers have been building in a 1-2% mortality improvement each year into their models, they have been mispricing their book for the last three decades.”

    2024 - November Clinical Mortality Longevity Risk Mortality Risk Volume 3 Issue 11 - November 2024
    Share. Twitter LinkedIn Email

    Related Posts

    New Report Highlights Tighter Regulatory Oversight of Asset-Intensive Reinsurance

    October 28, 2026By Greg Winterton

    Is Dementia the Next Big Longevity Event?

    October 15, 2026By Richard Marshall and Scott Hamilton

    The Structural Decision for Setting Up a Life Settlement Vehicle in Ireland

    September 23, 2026By Greg Winterton

    Insurers Sweeten Bulk Purchase Annuity Offers as Buy-Out Timetables – and Costs – Look Set To Increase

    August 26, 2026By Mark McCord
    Latest Issue

    Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

    November 11, 2026
    Litigation

    Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

    November 11, 2026

    Sponsor Demand Intact as US Pension Risk Transfer Market Prepares for Busy Year-End

    November 11, 2026

    New Report Highlights Tighter Regulatory Oversight of Asset-Intensive Reinsurance

    October 28, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.